jnj-42165279
Small moleculeexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2011 (NCT01650597)
Timeline
Indications
Mechanism of action
- Anandamide amidohydrolaseINHIBITOR
FAAH inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Nc1cnccc1Cl)N1CCN(Cc2ccc3c(c2)OC(F)(F)O3)CC1- Mol. weight
- 410.81 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297294 ↗
Also known as
- jnj-42165279
- jnj-42165279
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03664232 | Phase 2 | Oct 11, 2018 | Johnson and Johnson |
| NCT03564379 | Phase 1 | Jun 12, 2018 | Johnson and Johnson |
| NCT02498392 | Phase 2 | Oct 1, 2015 | Johnson and Johnson |
| NCT02432703 | Phase 2 | Jun 15, 2015 | Johnson and Johnson |
| NCT02169973 | Phase 1 | Feb 1, 2014 | Johnson and Johnson |
| NCT02065739 | Phase 1 | Jan 1, 2014 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01964651 | Phase 1 | Oct 1, 2013 | Johnson and Johnson |
| NCT01826786 | Phase 1 | Aug 1, 2013 | Johnson and Johnson |
| NCT01650597 | Phase 1 | Aug 1, 2011 | Johnson and Johnson |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 9 | 9 | 2 | 2011 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2014 |
2 organizations
Page 1 / 1